[1]张金华,田园,杨晓萍.参一胶囊辅助治疗原发性肝癌的系统评价[J].中国中医药图书情报杂志,2022,46(3):7-13.[doi:10.3969/j.issn.2095-5707.2022.03.002]
 ZHANG Jin-hua,TIAN Yuan,YANG Xiao-ping.Systematic Evaluation of Adjuvant Treatment of Primary Liver Cancer with Shenyi Capsules[J].Chinese Journal of Library and Information Science for Traditional Chinese Medicine,2022,46(3):7-13.[doi:10.3969/j.issn.2095-5707.2022.03.002]
点击复制

参一胶囊辅助治疗原发性肝癌的系统评价

参考文献/References:

[1] Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods[J]. International Journal of Cancer, 2019,144(8):1941-1953.
[2] 中华人民共和国国家卫生健康委员会医政医管局.原发性肝癌诊疗规范(2019年版)[J].中国实用外科杂志,2020,40(2):121-138.
[3] 张峰.人参皂甙对肝癌介入前后VEGF、AFPh的影响[J].山东医药,2007,47(13):39-40.
[4] 欧阳学农,余宗阳,杜建.人参皂甙Rg3胶囊联合肝动脉化疗栓塞术治疗中晚期肝癌的临床观察[J].临床肿瘤学杂志,2009,14(2):150-153.
[5] 周俭.肝动脉化疗栓塞术配合参一胶囊治疗原发性肝癌临床观察[J].实用中医药杂志,2011,27(11):762-763.
[6] 刘世贵,李欣.参一胶囊联合肝动脉栓塞治疗中晚期肝癌随机平行对照研究[J].实用中医内科杂志,2015,29(2):98-100.
[7] 龚耀,殷晓娟,刘长龙,等.参一胶囊联合肝动脉栓塞化疗治疗晚期原发性肝癌疗效观察[J].现代医药卫生,2015,31(23):3625-3627.
[8] 胡洋,王晶,李晶红,等.全肝介入化疗加参一胶囊联合治疗中晚期原发性肝癌效果分析[J].黑龙江医药科学,2016,39(2):35-36.
[9] ZHOU B, YAN Z P, LIU R, et al. Prospective study of transcatheter arterial chemoembolization (TACE) with ginsenoside Rg3 versus tace alone for the treatment of patients with advanced hepatocellular carcinoma[J]. Radiology, 2016,280(2):630-639.
[10] 谭栋,何盟国,沈乃营,等.参一胶囊联合腹腔镜解剖性肝段切除术治疗老年原发性肝癌的临床研究[J].中国中西医结合外科杂志,2018,24(1):21-26.
[11] 魏小娟,郭艳,王云溪.参一胶囊联合SOX方案治疗原发性肝癌的临床研究[J].中华中医药学刊,2019,37(11):2758-2761.
[12] 丁婕,戴旭,孟宪运,等.实体瘤疗效评价标准的研究进展[J].中国肿瘤临床与康复,2015,22(9):1150-1152.
[13] ZHOU M G, WANG H D, ZENG X Y, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990 - 2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. The Lancet, 2019,394(10204):1145-1158.
[14] Allemani C, Weir H K, Carreira H, et al. Global surveillance of cancer survival 1995 - 2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2)[J]. The Lancet, 2015,385(9972):977-1010.
[15] Torre L A, Bray F, Siegel R L, et al. Global cancer statistics, 2012[J]. CA: A Cancer Journal for Clinicians, 2015,65(2):87-108.
[16] CHEN W Q, ZHENG R S, Baade P D, et al. Cancer statistics in China, 2015[J]. CA: A Cancer Journal for Clinicians, 2016,66(2):115-132.
[17] 安宁,朱文.人参皂苷Rg3抗肿瘤作用机制研究进展[J].现代肿瘤医学,2008,16(4):648-652.
[18] 赵永军,李刚刚,孙治安.人参皂苷Rg3对肝细胞癌上皮间质转化的抑制作用机制研究[J].中国临床药理学杂志,2020,36(14):2066-2069.
[19] 方煊,李雅丽,陈新梅.人参皂甙单体Rg3抑制肝癌生长及其作用机制[J].中华中医药杂志,2016,31(9):3749-3751.
[20] 朴丽花,蔡英兰,张默函,等.人参皂甙Rg3在体外对肝癌细胞生长和凋亡的影响[J].中国临床药理学杂志,2012,28(9):659-661.
[21] 陈亚林.人参皂甙Rg3联合5-氟尿嘧啶对肝癌荷瘤小鼠的抑瘤作用[J].中国现代医学杂志,2012,22(19):29-31.
[22] 张金华.人参皂甙Rg3联合5-氟尿嘧啶对小鼠移植性肝癌细胞凋亡、血管形成作用的研究[D].石家庄:河北医科大学,2008.
[23] 张秀红.人参皂甙Rg3联合奥沙利铂、索拉非尼对于肝癌细胞凋亡的影响[J].临床医学研究与实践,2016,1(4):43,48.

备注/Memo

收稿日期:2021-09-27

第一作者:张金华,E-mail: okfrom@126.com

更新日期/Last Update:

2022-04-24